Giuseppe Carli

Vicenza, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Real-world experiences with subcutaneous therapy in adults with primary immune thrombocytopenia: A dual cross-sectional survey study of patients and clinicians in Italy.

Real-world experiences with subcutaneous therapy in adults with primary immune thrombocytopenia: A dual cross-sectional survey study of patients and clinicians in Italy.

Journal: Therapeutic advances in hematology

Published: December 24, 2025

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Journal: Hematological oncology

Published: November 13, 2025

Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study.

Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study.

Journal: British journal of haematology

Published: March 31, 2025

PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study.

PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study.

Journal: Annals of hematology

Published: March 26, 2025

Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries.

Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries.

Journal: Haematologica

Published: January 27, 2025

Predictors of Splenectomy Response in Immune Thrombocytopenia: A Multicentric Italian Study.

Predictors of Splenectomy Response in Immune Thrombocytopenia: A Multicentric Italian Study.

Journal: Journal of clinical medicine

Published: November 07, 2024

Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).

Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).

Journal: Cancer

Published: October 24, 2024

Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial.

Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial.

Journal: American journal of hematology

Published: April 11, 2024

Evans syndrome: Disease awareness and clinical management in a nation-wide ITP-NET survey.

Evans syndrome: Disease awareness and clinical management in a nation-wide ITP-NET survey.

Journal: European journal of haematology

Published: April 10, 2024

Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.

Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.

Journal: NEJM evidence

Published: February 06, 2024

A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements.

A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements.

Journal: Blood cancer journal

Published: December 08, 2023

Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.

Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.

Journal: Annals of hematology

Published: November 13, 2023

Showing 1-12 of 51

Last Updated: 09/26/2026